Enhanced brain distribution of carboplatin in a primate model after blood–brain barrier disruption using an implantable ultrasound device
- 8 December 2015
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 77 (1) , 211-216
Abstract
Glioblastoma is both the most common and aggressive primary brain tumor in adults. Carboplatin chemotherapy has shown only modest efficacy in progressive high-grade gliomas. The limited clinical efficacy of carboplatin may be due to its low concentration in tissue when the drug is delivered intravenously. The aim of this study was to assess whether the tissue concentration of intravenously administered carboplatin could be enhanced by ultrasound-induced blood–brain disruption in a primate model. Carboplatin was administered intravenously for 60 min to a single primate following blood–brain barrier opening induced by an implantable ultrasound device. Blood and brain samples were collected after animal killing, which occurred 60 min after the end of carboplatin administration. Platinum quantification in ultrafiltrate plasma and brain samples was performed using inductively coupled plasma mass spectrometry. The brain concentration of platinum was highly enhanced (5.2×) in the 3.9 cm3 region sonicated by the US beam, with a higher concentration in more vascularized anatomical structures. At 5 and 10 mm from the US beam axis, platinum concentrations were slightly enhanced (2.2× and 1.3× respectively). This study demonstrates that BBB opening using an implantable ultrasound transducer enhances the brain distribution of carboplatin in a loco-regional manner. Such a treatment approach is of significant interest for the treatment of primary brain tumors and is under current evaluation in a phase 1 clinical trial (NCT02253212).Keywords
This publication has 20 references indexed in Scilit:
- Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiformeJournal of Neuro-Oncology, 2014
- A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiformeContemporary Clinical Trials, 2012
- Tissue concentration of systemically administered antineoplastic agents in human brain tumorsJournal of Neuro-Oncology, 2011
- Carboplatin Chemotherapy in Patients with Recurrent High-grade GliomaClinical Oncology, 2011
- Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumorsJournal of Neuro-Oncology, 2010
- Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primatesCancer Chemotherapy and Pharmacology, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomasBrain Research Reviews, 2004
- Intravenous Carboplatin for Recurrent GliomasAmerican Journal of Clinical Oncology, 1996
- A phase II study of intravenous carboplatin for the treatment of recurrent gliomasJournal of Neuro-Oncology, 1994